Efficacy and Safety of Lacosamide as Adjunctive Therapy in Subjects ≥1 Month to <4 Years With Partial-onset Seizures

NCT ID: NCT02477839

Last Updated: 2021-07-01

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE3
• Total Enrollment: 255 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2015-06-05
• Study Completion Date: 2020-05-28

Brief Summary

The purpose of this trial is to assess the efficacy, safety and tolerability of lacosamide administered as add-on therapy with 1 to 3 anti-seizure medications. This trial is for children aged 1 month to less than 4 years with epilepsy who currently have uncontrolled partial-onset seizures.

Detailed Description

The trial consists of a 7-day Baseline Period, a 20-day Titration Period, a 7-day Maintenance Period, and a 12-day Transition Period for subjects who complete the study and choose to enter the extension study. Subjects who will not enter the extension study will continue after the Maintenance Period with a 16-day Taper Period followed by a 30-day Safety Follow-Up Period. The Taper Period and Safety Follow-Up are also applicable for subjects not eligible for continuation and therefore ending the study earlier.

If subjects meet the eligibility criteria, they will be randomized to receive either lacosamide 8 mg/kg/day to 12 mg/kg/day, or placebo during the Maintenance Phase. The dose of lacosamide will be titrated from 4 mg/kg/day at study start to maximum of 12 mg/kg/day at 4-day intervals of 1-2 mg/kg/day.

All subjects who complete the 20-day Titration Period will enter the 7-day Maintenance Period. No dose adjustment is allowed during the Maintenance Phase. The Treatment Phase is defined as the combined Titration and Maintenance Phases.

Conditions

Epilepsy With Partial-onset Seizures

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

Lacosamide

Lacosamide syrup 8 mg/kg/day to 12 mg/kg/day

Group Type: EXPERIMENTAL

Lacosamide

Intervention Type: DRUG

Active Substance: Lacosamide Pharmaceutical Form: Syrup Concentration: 10 mg/mL Route of Administration: oral

Placebo

Matching placebo syrup

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: OTHER

Active Substance: Placebo Pharmaceutical Form: Syrup Concentration: N/A Route of Administration: oral

Interventions

Lacosamide

Active Substance: Lacosamide Pharmaceutical Form: Syrup Concentration: 10 mg/mL Route of Administration: oral

Intervention Type: DRUG

Placebo

Active Substance: Placebo Pharmaceutical Form: Syrup Concentration: N/A Route of Administration: oral

Intervention Type: OTHER

Other Intervention Names

Vimpat; UCB Code: SPM 927; Abbreviated name: LCM; PBO

Eligibility Criteria

Inclusion Criteria

• Subject is male or female from >=1 month (ie, 4 weeks after full term [37 weeks gestational age]) to <4 years of age
• Subject has a diagnosis of epilepsy with partial-onset seizures. The results of >=1 prior EEG and >=1 magnetic resonance imaging/computerized tomography scan should be consistent with this diagnosis
• Subject weighs >=4 kg to <30 kg at Visit 1
• Subject has experienced >=2 partial-onset seizures with or without secondary generalization during each consecutive 7-day period during the 2 weeks prior to Visit 1
• Subject has >=2 partial-onset seizures with or without secondary generalization during the End-of-Baseline video-EEG. Electrographic seizures are defined as recognizable ictal patterns on an EEG involving >=2 contiguous electrodes. The seizures are initiated as a unilateral or strongly asymmetric abnormal epileptiform discharge lasting a total of >10 seconds
• Subject is on a stable (concurrently or sequentially) dosage regimen of 1 to 3 AEDs. The dosage regimen of concomitant AED therapy must be kept constant for a period of >=2 weeks prior to Visit 1. A stable daily dosage regimen of a concomitant benzodiazepine (BZD) will be considered as a concomitant AED
• Vagus nerve stimulation (VNS) is allowed and will not be counted as a concomitant AED. The VNS device must have been implanted for >=6 months prior to Visit 1; device settings must be kept stable for >=2 weeks prior to Visit 1 and kept stable during the Baseline, Treatment, and Transition Periods. Use of the VNS device magnet is allowed
• Subject is an acceptable candidate for venipuncture

• Subject has a current diagnosis of Lennox-Gastaut syndrome, epilepsia partialis continua, primary generalized epilepsy, Dravet Syndrome, or seizures that are not of partial-onset origin
• Subject has a history of generalized convulsive status epilepticus <=2 months prior to Screening (Visit 1)
• Subject has been treated with felbamate and has experienced any serious toxicity issues (defined as liver failure, aplastic anemia) with this treatment. Subjects treated with felbamate for <12 months are excluded. Subjects treated with felbamate for >=12 months prior to Visit 1 and who have not experienced serious toxicity issues are eligible
• Subject has an acute or subacutely progressive central nervous system disease. Subject has epilepsy secondary to a progressing cerebral disease or any other progressively neurodegenerative disease (malignant brain tumor or Rasmussen Syndrome)
• Subject has a known cardiac sodium channelopathy, such as Brugada syndrome

Exclusion Criteria

• Subject has experienced febrile seizures exclusively. The occurrence of febrile seizures in addition to partial-onset seizures is not exclusionary
• Subject is on a ketogenic diet that has either changed within the 4 weeks prior to Visit 1 or is expected to change during the study
• Subject has creatinine clearance <30 mL/minute
• Subject has a clinically relevant ECG abnormality, in the opinion of the investigator (eg, second or third degree heart block at rest or a corrected QT interval [QTc] >=450 ms)
• Subject has a hemodynamically significant congenital heart disease
• Subject has an arrhythmic heart condition requiring medical therapy
• Subject has a known history of severe anaphylactic reaction secondary to medication intake or serious blood dyscrasias

• Minimum Eligible Age: 1 Month
• Maximum Eligible Age: 47 Months
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

UCB BIOSCIENCES, Inc.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

UCB Cares

Role: STUDY_DIRECTOR

+1 877 822 9493 (UCB)

Locations

Sp0967 638

Birmingham, Alabama, United States

Sp0967 117

Tampa, Florida, United States

Sp0967 115

Henderson, Nevada, United States

Sp0967 120

Lebanon, New Hampshire, United States

Sp0967 129

Dallas, Texas, United States

Sp0967 630

San Antonio, Texas, United States

Sp0967 643

San Antonio, Texas, United States

Sp0967 142

Córdoba, , Argentina

Sp0967 158

Passo Fundo, , Brazil

Sp0967 152

Porto Alegre, , Brazil

Sp0967 150

São Paulo, , Brazil

Sp0967 154

São Paulo, , Brazil

Sp0967 310

Plovdiv, , Bulgaria

Sp0967 530

Beijing, , China

Sp0967 535

Changchun, , China

Sp0967 532

Chongqing, , China

Sp0967 536

Nanchang, , China

Sp0967 531

Shanghai, , China

Sp0967 537

Shenzhen, , China

Sp0967 613

Osijek, , Croatia

Sp0967 610

Rijeka, , Croatia

Sp0967 612

Zagreb, , Croatia

Sp0967 320

Ostrava-Poruba, , Czechia

Sp0967 349

Marseille, , France

Sp0967 346

Rennes, , France

Sp0967 344

Strasbourg, , France

Sp0967 620

Tbilisi, , Georgia

Sp0967 621

Tbilisi, , Georgia

Sp0967 622

Tbilisi, , Georgia

Sp0967 623

Tbilisi, , Georgia

Sp0967 542

Athens, , Greece

Sp0967 361

Budapest, , Hungary

Sp0967 362

Budapest, , Hungary

Sp0967 363

Budapest, , Hungary

Sp0967 364

Budapest, , Hungary

Sp0967 368

Budapest, , Hungary

Sp0967 374

Petah Tikva, , Israel

Sp0967 397

Genova, , Italy

Sp0967 398

Messina, , Italy

Sp0967 381

Milan, , Italy

Sp0967 700

Napoli, , Italy

Sp0967 383

Roma, , Italy

Sp0967 395

Roma, , Italy

Sp0967 694

Aguascalientes, , Mexico

Sp0967 561

Chihuahua City, , Mexico

Sp0967 569

Culiacán, , Mexico

Sp0967 693

Culiacán, , Mexico

Sp0967 563

Guadalajara, , Mexico

Sp0967 564

México, , Mexico

Sp0967 568

Monterrey, , Mexico

Sp0967 692

Monterrey, , Mexico

Sp0967 650

Chisinau, , Moldova

Sp0967 720

Cebu, , Philippines

Sp0967 724

Cebu, , Philippines

Sp0967 721

Manila, , Philippines

Sp0967 723

Manila, , Philippines

Sp0967 727

Quezon City, , Philippines

Sp0967 422

Krakow, , Poland

Sp0967 750

Lisbon, , Portugal

Sp0967 581

Bucharest, , Romania

Sp0967 582

Iași, , Romania

Sp0967 573

Sibiu, , Romania

Sp0967 577

Timișoara, , Romania

Sp0967 454

Kemerovo, , Russia

Sp0967 456

Nizhny Novgorod, , Russia

Sp0967 452

Novosibirsk, , Russia

Sp0967 453

Omsk, , Russia

Sp0967 455

Perm, , Russia

Sp0967 730

Smolensk, , Russia

Sp0967 458

Tomsk, , Russia

Sp0967 459

Ulyanovsk, , Russia

Sp0967 450

Yekaterinburg, , Russia

Sp0967 461

Belgrade, , Serbia

Sp0967 464

Belgrade, , Serbia

Sp0967 463

Novi Sad, , Serbia

Sp0967 474

Bratislava, , Slovakia

Sp0967 212

Seoul, , South Korea

Sp0967 215

Seoul, , South Korea

Sp0967 224

Taipei, , Taiwan

Sp0967 237

Bangkok, , Thailand

Sp0967 235

Pathum Wan, , Thailand

Sp0967 602

Dnipro, , Ukraine

Sp0967 609

Dnipro, , Ukraine

Sp0967 681

Ivano-Frankivsk, , Ukraine

Sp0967 600

Kiev, , Ukraine

Sp0967 606

Kiev, , Ukraine

Sp0967 682

Uzhhorod, , Ukraine

Sp0967 603

Vinnytsia, , Ukraine

Countries

United States; Argentina; Brazil; Bulgaria; China; Croatia; Czechia; France; Georgia; Greece; Hungary; Israel; Italy; Mexico; Moldova; Philippines; Poland; Portugal; Romania; Russia; Serbia; Slovakia; South Korea; Taiwan; Thailand; Ukraine

Provided Documents

Document Type: Study Protocol

View Document

Document Type: Statistical Analysis Plan

View Document

Other Identifiers

2013-000717-20

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

SP0967

Identifier Type: -

Identifier Source: org_study_id